V
Vaxcyte, Inc. (PCVX)
NMS – Real Time Price. Currency in USD
53.16
-1.55 (-2.83%)
At close: Mar 27, 2026, 4:00 PM EDT
53.00
-0.16 (-0.30%)
After-hours: Mar 27, 2026, 5:48 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
53.16
-1.55 (-2.83%)
At close: Mar 27, 2026, 4:00 PM EDT
53.00
-0.16 (-0.30%)
After-hours: Mar 27, 2026, 5:48 PM EDT
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Name | Position |
|---|---|
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO |
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director |
| Mr. Harp Dhaliwal M.B.A. | Chief Technical Operations Officer |
| Mr. James T. Wassil M.B.A., M.S. | Executive VP & COO |
| Mr. Jeff Macdonald | Executive Director of Investor Relations |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary |
| Date | Type | Document |
|---|---|---|
| 2026-02-02 | 8-K | d54534d8k.htm |
| 2025-12-19 | 8-K | pcvx-20251218.htm |
| 2025-11-04 | 8-K | pcvx-20251104.htm |
| 2025-09-30 | 8-K | pcvx-20250924.htm |
| 2025-08-06 | 10-Q | pcvx-20250630.htm |
| 2025-06-17 | 8-K | pcvx-20250612.htm |
| 2025-05-07 | 8-K | pcvx-20250507.htm |
| 2025-05-01 | 8-K | pcvx-20250501.htm |
| 2025-04-28 | ARS | d897654dars.pdf |
| 2025-04-18 | PRE 14A | d900798dpre14a.htm |
| Ms. Elvia Cowan |
| Senior VP of Finance & Chief Accounting Officer |
| Ms. Janet Graesser | Senior Vice President of Corporate Affairs |
| Ms. Whitney Jones | Chief People Officer |